Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Loss and Comprehensive Loss

v3.24.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue $ 0 $ 0
Expenses:    
Research and development, related party 3,492 3,556
Research and development 33,273 24,532
General and administrative 15,591 14,514
Operating expenses 52,356 42,602
Other income :    
Interest income 1,151 788
Foreign exchange loss (2) (9)
Total other income 1,149 779
Net loss (51,207) (41,823)
Other comprehensive loss:    
Unrealized gain (loss) on securities available-for-sale securities 2 (2)
Total comprehensive loss $ (51,205) $ (41,825)
Basic loss per common share $ (7.58) $ (6.8)
Diluted loss per common share $ (7.58) $ (6.8)
Weighted average number of common shares outstanding used in the calculation of basic per share (in shares) 6,755 6,151
Weighted average number of common shares outstanding used in the calculation of diluted loss per share (in shares) 6,755 6,151